Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer
The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.
1. A method for therapeutic treatment of existing basal cell carcinoma (BCC) comprising administering to a subject in need of treatment of basal cell carcinoma an effective amount of a 2,5-dihydroxybenzene derivative selected from: 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, 5-(acetyloxy)-2-hydroxy benzene sulfonic acid and 2,5-bis(acetyloxy)benzenesulfonic acid.
2. The method of claim 1 , wherein the 2,5-dihydroxybenzene derivative is administered topically.
3. The method of claim 1 , wherein the 2,5-dihydroxybenzene derivative is administered orally, buccally, transdermally, by inhalation, rectally, intravaginally, intraocularly, or otically.
4. The method of claim 1 , further comprising administration of at least one additional therapeutic agent.
5. The methid of claim 1 , further comprising at least one coadjuvant therapy selected from the group consisting of: photodynamic therapy, cryotherapy, curettage, and surgery.
6. The method of claim 2 , wherein the 2,5-dihydroxybenzene derivative is administered at least once per week.
7. The method of claim 6 , wherein the 2,5-dihydroxybenzene derivative is administered at least once per day.
8. The method of claim 7 , wherein the 2,5-dihydroxybenzene derivative is administered at least twice per day.
9. The method of claim 2 , wherein the 2,5-dihydroxybenzene derivative is present in a pharmaceutical composition in an amount of about 0.001% to about 30% w/w.
10. The method of claim 9 , wherein the 2,5-dihydroxybenzene derivative is present in a pharmaceutical composition in an amount of about 2.5% w/w.
11. The method of claim 10 , wherein the 2,5-dihydroxybenzene derivative is present in a pharmaceutical composition in an amount of about 5% w/w.
12. The method of claim 11 , wherein the 2,5-dihydroxybenzene derivative is present in a pharmaceutical composition in an amount of about 10% w/w.
13. The method of claim 12 , wherein the 2,5-dihydroxybenzene derivative is present in a pharmaceutical composition in an amount of about 15% w/w.
14. The method of claim 2 , wherein the 2,5-dihydroxybenzene derivative is administered over a period of about one week.
15. The method of claim 14 , wherein the 2,5-dihydroxybenzene derivative is administered over a period of about four weeks.
16. The method of claim 9 , wherein the 2,5-dihydroxybezene derivative is present in a pharmaceutical composition in an amount of about 1% w/w.